| Recruiting | Phase II Clinical Trial Evaluating the Efficacy and Safety of HRS-7249 and SHR-1918 in Patients With Severe Hy Severe Hypertriglyceridemia With a High Risk of Acute Pancreatitis | Phase 2 | 2026-02-25 |
| Recruiting | Phase II Clinical Study of HRS-9563 in Patients With Mild to Moderate Hypertension Mild to Moderate Hypertension | Phase 2 | 2026-01-14 |
| Recruiting | Phase II Clinical Study of HRS-9057 Injection in Patients With Heart Failure-induced Fluid Retention Fluid Retention Caused by Heart Failure | Phase 2 | 2025-12-31 |
| Active Not Recruiting | A Study Comparing the Efficacy and Safety of HRS9531 Injection With Semaglutide Injection in Subjects With Obe Obesity | Phase 3 | 2025-12-25 |
| Recruiting | HRS-7450 Injection Phase II Clinical Trial for Acute Ischemic Stroke. Acute Ischemic Stroke | Phase 2 | 2025-10-31 |
| Active Not Recruiting | A Study of HRS-5632 in Adult Participants With Elevated Lipoprotein(a) at High Risk for Cardiovascular Events Lipoprotein Disorder | Phase 2 | 2025-10-21 |
| Recruiting | Relative Bioavailability of First vs Second-Generation Formulations of HRS9531 Tablets in Obese or Overweight Overweight or Obesity | Phase 1 | 2025-10-15 |
| Recruiting | A Single Ascending Dose of HRS-2162 in Healthy Subjects Reversal of Neuromuscular Blockade | Phase 1 | 2025-09-25 |
| Recruiting | A Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study to Evaluate the Efficacy Subjects With Moderate-to-severe OSA and Obesity Who Are on PAP Therapy | Phase 3 | 2025-08-13 |
| Recruiting | A Clinical Study Evaluating the Efficacy and Safety of HRS-7249 in Treating Patients With Hyperlipidemia Hyperlipidemia | Phase 2 | 2025-08-12 |
| Recruiting | Efficacy and Safety of HRS9531 in Participants With Type 2 Diabetes Treated With Basal Insulin Type 2 Diabetes | Phase 3 | 2025-07-25 |
| Recruiting | A Phase III Study Evaluating the Efficacy and Safety of HRS9531 Injection in Subjects With Obstructive Sleep A Bstructive Sleep Apnea (OSA) and Obesity | Phase 3 | 2025-07-25 |
| Recruiting | A Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-5817 Inject Obesity, Overweight | Phase 1 | 2025-05-08 |
| Completed | Mass Balance Study of [14C]HRS9531 in Healthy Male Subjects Type 2 Diabetes Mellitus, Weight Loss | Phase 1 | 2025-04-21 |
| Completed | Efficacy and Safety of HRS9531 Tablet in Obese Subjects Chronic Management of Body Weight | Phase 2 | 2025-04-07 |
| Completed | The Evaluation of Bioequivalence Between a Single-dose Pen and a Multi-dose Pen of HRS9531 Injection Solution Overweight/Obesity | Phase 1 | 2025-02-11 |
| Recruiting | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-4729 Injection in H Overweight or Obesity | Phase 1 | 2025-01-16 |
| Recruiting | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Subcutaneous Injection of HRS-9563 in Subjects With Mild Hypertension | Phase 1 | 2024-12-24 |
| Completed | Influence of HRS9531 on Gastric Emptying and Pharmacokinetics of Metformin, Atorvastatin, Warfarin, and Digoxi Type 2 Diabetes | Phase 1 | 2024-12-18 |
| Completed | A Phase I Clinical Study of a Single Subcutaneous Injection of HRS-5632 in Healthy Subjects Dyslipidemia | Phase 1 | 2024-12-02 |
| Active Not Recruiting | the Efficacy and Safety of HRS9531 Injection in Subjects With Type 2 Diabetes， Inadequately Controlled With Di Diabetes Mellitus, Type 2 | Phase 3 | 2024-11-08 |
| Completed | Influence of HRS9531 on Pharmacokinetics of Metformin in Healthy Subjects Type 2 Diabetes | Phase 1 | 2024-11-05 |
| Active Not Recruiting | A Study of HRS9531 Versus Semaglutide Once Weekly as Add-on Therapy to Metformin Monotherapy or in Combination Type 2 Diabetes | Phase 3 | 2024-10-31 |
| Completed | HR20013 for Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents Nausea and Vomiting Associated With Moderate Emetic Risk Anticancer Agents | Phase 3 | 2024-09-03 |
| Not Yet Recruiting | A Multicenter, Randomized, Double-blind, Placebo-parallel-controlled Phase II Clinical Study Evaluating the Ef Obese Subjects With Polycystic Ovary Syndrome (PCOS) | Phase 2 | 2024-09-01 |
| Completed | A Study of HRS-9057 in Patients With Heart Failure and Volume Overload Heart Failure With Volume Overload | Phase 1 | 2024-08-16 |
| Completed | A Study on Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS-7249 Injection in Healthy Subjec Hyperlipidemia | Phase 1 | 2024-08-15 |
| Completed | Safety, Tolerability, and Preliminary Efficacy of HRS-7450 Injection in the Treatment of Acute Ischemic Stroke Acute Ischemic Stroke | Phase 1 | 2024-08-06 |
| Not Yet Recruiting | Investigation of Optimal Dosage Regimen for HRS9531 Tablets in Healthy Subjects Overweight or Obese, Type 2 Diabetes | Phase 1 | 2024-08-05 |
| Not Yet Recruiting | A Study of HRS9531 Injection in Obese Subjects With Obstructive Sleep Apnea Weight Management | Phase 2 | 2024-08-01 |
| Completed | A Trial of HRS5580 in Prevention of Postoperative Nausea and Vomiting of Adults Preventing of Postoperative Nausea and Vomiting in Adults | Phase 2 | 2024-06-25 |
| Recruiting | A Multicenter, Randomized, Open, Parallel-designed Study to Evaluate the Efficacy and Safety of HRS-5635 Injec Chronic Hepatitis B | Phase 2 | 2024-06-06 |
| Completed | A Study of Single and Multiple Doses HRS9531 Tablets in Healthy Subjects Overweight or Obesity; Type 2 Diabetes | Phase 1 | 2024-06-04 |
| Completed | To Compare the Efficacy and Safety of HRS9531 and Placebo in Subjects With Overweight or Obese Overweight or Obesity | Phase 3 | 2024-05-13 |
| Active Not Recruiting | HRS9531 Injection in Obese Subjects With Heart Failure With Preserved Ejection Fraction Heart Failure With Preserved Ejection Fraction | Phase 2 | 2024-05-06 |
| Recruiting | A Trial of Intravenous HRS9432 in the Treatment of Subjects With Candidemia and/or Invasive Candidiasis Patients With Candidemia and/or Invasive Candidiasis | Phase 2 | 2024-04-27 |
| Unknown | A Study of HRS9531 in Participants With Impaired Kidney Function and Healthy Subjects Type 2 Diabetes | Phase 1 | 2024-02-28 |
| Unknown | Efficacy and Safety of HRS9531 Injections in Overweight or Obese Subjects Overweight or Obesity | Phase 2 | 2023-10-01 |
| Unknown | A Trial of HRS-7450 in Chinese Healthy Volunteers Cerebral Stroke | Phase 1 | 2023-10-01 |
| Completed | Efficacy and Safety of HRS9531 Injection in Type 2 Diabetes Subjects Type 2 Diabetes | Phase 2 | 2023-08-12 |
| Completed | Efficacy and Safety of HRS9531 Injection in Obese Subjects Without Diabetes Overweight or Obesity | Phase 2 | 2023-06-13 |
| Completed | A Relative Bioavailability Study of HRS9531 in Healthy Subjects Type 2 Diabetes | Phase 1 | 2023-05-15 |
| Unknown | Clinical Study to Evaluate the Safety, Tolerance and Pharmacokinetic Characteristics of Single Administration Chronic Hepatitis B | Phase 1 | 2023-04-30 |
| Unknown | A Phase Ⅲ Study of HR19006 Injection in Postsurgical Parenteral Nutrition Parenteral Nutrition | Phase 3 | 2023-04-28 |
| Completed | A Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of HRS3797 in Healthy Subj Skeletal Muscle Relaxation | Phase 1 | 2023-02-15 |
| Completed | A Study of Remimazolam Tosilate for Sedation in the ICU Sedation in the ICU | Phase 2 | 2022-10-12 |
| Completed | Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Subcutaneous Injections of HRS9531 in Diabetes Mellitus, Type 2 | Phase 1 | 2022-10-12 |
| Completed | Clinical Study of HR20013 for Injection in Patients With Malignant Solid Tumors Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy | Phase 3 | 2022-09-21 |
| Completed | Study of HR20013 for Injection in Patients With Malignant Solid Tumors Prevention of Nausea and Vomiting Caused by Highly Emetogenic Chemotherapy | Phase 1 | 2022-08-30 |
| Completed | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of HRS9531 in Healthy Subjects Type 2 Diabetes | Phase 1 | 2021-12-06 |